A recent investigation by Northwestern Medicine researchers suggests that while coronary artery calcium scans are gaining traction for assessing future heart disease risk, their utility is most pronounced in a specific subset of patients. The study, which monitored over 6,000 adults for a decade, revealed that these scans offer marginal additional predictive power beyond the American Heart Association's PREVENT risk calculator for the general population. However, for individuals initially categorized into borderline or intermediate risk groups by PREVENT, the calcium scans provided crucial insights, clarifying who was truly at higher or lower risk of developing heart conditions.
Targeted Application of Coronary Artery Calcium Scans Unveiled
Published on August 26, 2026, in the prestigious journal JAMA, this Northwestern Medicine study sheds light on the optimal application of coronary artery calcium (CAC) scans. Dr. Nilay Shah, a senior author of the study and an assistant professor of medicine in the cardiology division at Northwestern University Feinberg School of Medicine, emphasized that despite the increasing availability and decreasing cost of CAC scans, not all individuals derive significant benefit from them. The research indicates that routine screening for low-risk individuals may result in unnecessary radiation exposure, additional testing, and financial burdens without clear clinical advantages. Similarly, for high-risk patients who are already candidates for statin therapy, a CAC scan might be redundant, as treatment recommendations would likely remain unchanged. The study's methodology involved analyzing data from over 6,000 adults, aged 45 to 79, who were part of the Multi-Ethnic Study of Atherosclerosis. At the study's outset, participants underwent CAC scoring and received a 10-year cardiovascular event risk estimate via the PREVENT calculator. Over the subsequent decade, 6% of participants experienced a heart attack or stroke. A comparison of predictive models, with and without CAC scores, demonstrated only a modest improvement in overall risk discrimination (from 0.73 to 0.75) when CAC data was included. However, a more detailed analysis focusing on individuals classified as borderline or intermediate risk (those with an initial 3% to 9% 10-year heart disease risk) revealed a substantial enhancement in predictive accuracy. For this specific group, CAC scores offered a clearer, more nuanced understanding of individual risk levels, which can significantly influence treatment strategies. Dr. Shah underscored the importance of these findings, stating that they refine clinical guidance on who can most benefit from preventive measures, such as statin use. The study also validated the effectiveness of the PREVENT calculator as a standalone tool for cardiovascular risk assessment. Future research will explore the utility of CAC scores in high-risk demographic groups, such as South Asian and Filipino adults, and in younger populations, as this study primarily focused on individuals aged 45 to 79.
This research offers a critical perspective on the judicious use of diagnostic tools in preventive medicine. By identifying the patient populations most likely to benefit from CAC scans, healthcare providers can optimize resource allocation, minimize unnecessary procedures, and deliver more personalized and effective cardiovascular care. The findings underscore a move towards more targeted screening approaches, ensuring that advanced diagnostic technologies are utilized where they can make the most significant clinical impact.